Login
$AKBA
$0.47 +$0.02 (5.1%) After hours

$AKBA SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more

Date of Report (Date of earliest event reported): November 12, 2026

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025

23 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the...

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company for personal reasons. His...

10 Aug 2026 Form 4: Butler John P., Director

Received 350,000 shares by exercise or conversion ($221K)

05 Aug 2026 S-8
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy

01 Jul 2026 Form 4: Ostrowski Erik, SVP, CFO, CBO & Treasurer

Sold 56,019 shares ($62.2K)

30 Jun 2026 8-K: Regulation FD Disclosure; Other Events

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

29 Jun 2026 144
22 Jun 2026 Form 4: Wolf Myles, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Smith Cynthia, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Rogers Michael W, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Frieson Ron, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Akebia Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the...

22 Jun 2026 Form 4: Zumwalt Leanne M, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Adams Adrian, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

12 May 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support